date, no therapeutic drug concentrations of aripiprazole have been established. Although quantitative data are limited with respect to the drug’s bio-availability, Yokoi et al. reported that administration of tablet aripiprazole for 14 days in 15 males, in doses of 0.5, 1, 2, 10, and 30 mg/day, resulted in dose-dependent receptor occupancy between 40% and 95%. [...]

Although minimal side effects from aripiprazole table have been reported, complete clinical data have not yet been established. In a 52-week study reported by Bristol-Myers Squibb, 1,294 patients with schizophrenia were evaluated to establish efficacy, safety, and tolerabil-ity. Patients taking aripiprazole experienced significantly fewer extrapyramidal symptoms than patients taking haloperi-dol. The most commonly reported adverse [...]

INTRODUCTION
Although early antipsychotic agents, such as chlorpromazine drug (Thorazine tablet, GlaxoSmithKline) and haloperidol (Haldol®, Ortho-McNeill) showed great promise initially, their limitations became evident when extrapyramidal side effects were associated with their use. Subsequently, the novel atypical antipsychotics, such as generic clozapine (Clozaril drug, Novartis), risperidone drug (Risperdal canadian, Janssen), canadian olanzapine (Zyprexa generic, Eli Lilly), [...]